The Drug Budget Silo Mentality in Europe: An Overview

Garrison, LP; Towse, Adrian

doi:10.1046/j.1524-4733.6.s1.1.x

Cited by 44 publications

(36 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the Irish population has greater than ever access to information regarding health, new treatments and preventative actions and finally health is a becoming primary concern for consumers. Most countries struggle to reduce pharmaceutical spending as escalating costs and limited resources threaten other budgetary priorities [12,13]. Initiatives that have targeted doctors in the past to reduce pharmaceutical spending include guidelines, fund-holding, and others [14,15].…”

Section: Discussionmentioning

confidence: 99%

Doctors’ attitudes about prescribing and knowledge of the costs of common medications

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Doctors’ attitudes about prescribing and knowledge of the costs of common medications

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Such budgets for specific types of health care services and problems associated with a "budget silo mentality" have been described and analyzed for pharmaceuticals (Garrison and Towse 2003). For genetic tests, similar arrangements can be found in Sweden, where hospitals are assigned budgets for genetic services.…”

Section: Financial Benefits and Costsmentioning

confidence: 99%

Points to consider in assessing and appraising predictive genetic tests

Rogowski

Grosse²,

John

et al. 2010

J Community Genet

View full text Add to dashboard Cite

The use of predictive genetic tests is expanding rapidly. Given limited health care budgets and few national coverage decisions specifically for genetic tests, evidence of benefits and harms is a key requirement in decision making; however, assessing the benefits and harms of genetic tests raises a number of challenging issues. Frequently, evidence of medical benefits and harms is limited due to practical and ethical limitations of conducting meaningful clinical trials. Also, clinical endpoints frequently do not capture the benefit appropriately because the main purpose of many genetic tests is personal utility of knowing the test results, and costs of the tests and counseling can be insufficient indicators of the total costs of care. This study provides an overview of points to consider for the assessment of benefits and harms from genetic tests in an ethically and economically reflected manner. We discuss whether genetic tests are sufficiently exceptional to warrant exceptional methods for assessment and appraisal.

show abstract

“…1 Four were employed in public sector, five in different areas of the private sector (company or association), and three were members of other associations. The informants were selected according to the following criteria: a prominent position, active participation in public debate, and involvement in the formation of pharmaceutical policies.…”

Section: Qualitative Interviewsmentioning

confidence: 99%

“…Both clinical and economic interests have traditionally been balanced in various ways, and since public pharmaceutical costs have risen faster than health expenditures in general [1], the control of the pharmaceutical costs has been a reason of increasing governmental concern since the early 1990s [2][3][4].…”

Section: Introductionmentioning

confidence: 99%